Document Detail

Novel approaches to the pharmacotherapy of pulmonary arterial hypertension.
MedLine Citation:
PMID:  19121410     Owner:  NLM     Status:  MEDLINE    
Pulmonary arterial hypertension (PAH) has evolved from an untreatable condition to a disease for which several classes of drugs have now been approved, including various prostanoids, endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Because the pathogenesis of pulmonary hypertension is increasingly understood, various new substances are now under clinical investigation, including serotonin antagonists, vasoactive intestinal peptide, stimulators of soluble guanylate cyclase and tyrosine kinase inhibitors. Several of these compounds hold promise for the future therapy of PAH, especially as regression of pulmonary vascular remodeling appears to become a realistic possibility with the combination of established and novel treatments.
Karen M Olsson; Marius M Hoeper
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review     Date:  2009-01-20
Journal Detail:
Title:  Drug discovery today     Volume:  14     ISSN:  1878-5832     ISO Abbreviation:  Drug Discov. Today     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-03-16     Completed Date:  2009-05-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  England    
Other Details:
Languages:  eng     Pagination:  284-90     Citation Subset:  IM    
Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Clinical Trials as Topic
Drug Delivery Systems*
Drug Therapy, Combination
Hypertension, Pulmonary / drug therapy*,  physiopathology
Pulmonary Artery / pathology

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Kinase-targeted libraries: the design and synthesis of novel, potent, and selective kinase inhibitor...
Next Document:  G-protein-coupled receptor-focused drug discovery using a target class platform approach.